(Q34636994)

3 August 2017

1 reference

title

Orthopaedic surgery in haemophilic patients with inhibitors: an overview (English)

1 reference

3 August 2017

0 references

I Hvid

1

1 reference

3 August 2017

E C Rodriguez-Merchan

series ordinal

2

1 reference

3 August 2017

publication date

1 May 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

8

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

288-291

1 reference

Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00607.X

Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00607.X

Clinical use of recombinant FVIIa (rFVIIa).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00607.X

Porcine factor VIII and plasmapheresis in the management of hemophiliac patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00607.X

Use of activated prothrombin complex concentrate over multiple surgical episodes in a hemophilic child with an inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00607.X

Management of haemophilia in patients with high-titre inhibitors: focus on the evolution of activated prothrombin complex concentrate AUTOPLEX T.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00607.X

Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00607.X

Successful hemostasis during a major orthopedic operation by using recombinant activated factor VII in a patient with severe hemophilia A and a potent inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00607.X

Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00607.X

Hemophilia. Treatment of patients with inhibitors: cost issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00607.X

Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00607.X

Recombinant FVIIa (NovoSeven) continuous infusion and total hip replacement in patients with haemophilia and high titre of inhibitors to FVIII: experience of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00607.X

Knee joint arthroplasty in a patient with haemophilia A and high inhibitor titre using recombinant factor VIIa (NovoSeven): a new case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00607.X

10.1046/J.1365-2516.2002.00607.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference